| Nov 13 |
Earnings Scheduled For November 13, 2024
|
| Nov 7 |
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
|
| Nov 5 |
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers
|
| Oct 31 |
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024
|
| Oct 30 |
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024
|
| Oct 15 |
Lucid Diagnostics gets notice of allowance for patent underlying its esoguard esophageal DNA test
|
| Oct 15 |
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test
|
| Oct 10 |
PAVmed subsidiary, Veris Health, awarded $1.8M NIH grant to enhance cancer care
|
| Oct 10 |
PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care
|
| Oct 9 |
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit
|
